DNLI (Denali Therapeutics Inc.) Stock Financials & Earnings | Market Cap Arena

DNLI (Denali Therapeutics Inc.) Stock Financials & Earnings | Market Cap Arena

DNLIDenali Therapeutics Inc.

Mkt Cap$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$513M

EPS (TTM)-$2.97

Free Cash Flow (TTM)-$422M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$35M	$35M	-$121M
Q2 23	$294M	$294M	$170M
Q3 23	$1M	$1M	-$114M
Q4 23	$0	$0	-$133M
Q1 24	$0	$0	-$118M
Q2 24	$0	$0	-$117M
Q3 24	$0	$0	-$123M
Q4 24	$0	$0	-$130M
Q1 25	$0	$0	-$146M
Q2 25	$0	$0	-$135M
Q3 25	$0	$0	-$137M
Q4 25	$0	-$3M	-$137M

Valuation

Quarter	P/S	P/E
Q1 23	33.3x	—
Q2 23	9.9x	—
Q3 23	9.9x	—
Q4 23	10.2x	—
Q1 24	11.4x	—
Q2 24	2667.8x	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$59M	-$62M
Q2 23	-$113M	-$119M
Q3 23	-$87M	-$89M
Q4 23	-$99M	-$101M
Q1 24	-$114M	-$116M
Q2 24	-$91M	-$96M
Q3 24	-$59M	-$63M
Q4 24	-$84M	-$89M
Q1 25	-$131M	-$137M
Q2 25	-$75M	-$80M
Q3 25	-$107M	-$106M
Q4 25	-$99M	-$100M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$3M
Q2 23	$6M
Q3 23	$2M
Q4 23	$2M
Q1 24	$2M
Q2 24	$5M
Q3 24	$4M
Q4 24	$5M
Q1 25	$5M
Q2 25	$4M
Q3 25	$1M
Q4 25	$2M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-16.6%	+43.6%
Q2 23	+460.4%	+8.6%
Q3 23	-64.4%	+3.6%
Q4 23	-100.0%	+14.7%
Q1 24	-100.0%	-24.5%
Q2 24	-100.0%	-5.7%
Q3 24	-100.0%	+7.1%
Q4 24	—	-2.1%
Q1 25	—	+23.7%
Q2 25	—	+15.8%
Q3 25	—	+11.6%
Q4 25	—	+5.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$28M	79.9%
Q2 23	$0	0.0%
Q3 23	$27M	2167.3%
Q4 23	$26M	—
Q1 24	$28M	—
Q2 24	$25M	—
Q3 24	$0	—
Q4 24	$25M	—
Q1 25	$25M	—
Q2 25	$0	—
Q3 25	$0	—
Q4 25	$24M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$129M	$27M	—
Q2 23	$98M	$26M	—
Q3 23	$90M	$25M	—
Q4 23	$108M	$25M	—
Q1 24	$107M	$25M	—
Q2 24	$91M	$25M	—
Q3 24	$98M	$25M	—
Q4 24	$100M	$30M	—
Q1 25	$116M	$29M	—
Q2 25	$103M	$32M	—
Q3 25	$102M	$35M	—
Q4 25	$98M	—	$37M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$68M	$1.2B	$1.3B
Q2 23	$132M	$1.1B	$1.2B
Q3 23	$148M	$961M	$1.1B
Q4 23	$127M	$907M	$1.0B
Q1 24	$61M	$876M	$937M
Q2 24	$75M	$821M	$896M
Q3 24	$91M	$746M	$837M
Q4 24	$175M	$657M	$832M
Q1 25	$57M	$761M	$818M
Q2 25	$141M	$758M	$899M
Q3 25	$91M	$757M	$848M
Q4 25	$205M	$663M	$868M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	137M	+2.7%
Q2 23	141M	+3.2%
Q3 23	138M	-2.3%
Q4 23	138M	+0.4%
Q1 24	149M	+8.1%
Q2 24	169M	+13.0%
Q3 24	169M	+0.4%
Q4 24	170M	+0.4%
Q1 25	171M	+0.7%
Q2 25	171M	+0.1%
Q3 25	172M	+0.6%
Q4 25	175M	+1.8%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 15	—	—
FY 16	—	—
FY 17	$0	130
FY 18	$722K	179
FY 19	$102K	261
FY 20	$1M	291
FY 21	$128K	380
FY 22	$254K	427
FY 23	$743K	445
FY 24	$0	422
FY 25	$0	30K